What is Zepbound, explained

What this guide covers

Zepbound is tirzepatide, a once-weekly injection that acts on two gut hormones, GIP and GLP-1, approved for chronic weight management and sleep apnea. What it is, how it differs from Mounjaro, and what to know. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• The short answer. Zepbound is the brand name for tirzepatide, the same active drug as Mounjaro, made by Eli Lilly, approved specifically for chronic weight management rather than diabetes. It is a once-weekly injection and a dual agonist, meaning it activates two gut-hormone receptors at once, GIP and GLP-1, rather than the single GLP-1 receptor that semaglutide (Ozempic, Wegovy) targets. The one thing worth fixing in your mind: Zepbound and Mounjaro are not different drugs, they are the same molecule at the same doses with different labels. Zepbound is the weight-management brand; Mounjaro is the diabetes brand. The dual GIP and GLP-1 mechanism is the leading explanation for why tirzepatide's effects in trials tend to be large.
• Who makes Zepbound, and what it is approved for. Zepbound is made by Eli Lilly. The FDA approved it for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, alongside reduced-calorie diet and increased activity. It also carries a second approval that the semaglutide drugs do not have in this exact form: moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. That sleep-apnea indication is genuinely distinctive and is why some people are prescribed Zepbound for reasons beyond weight alone. Your prescriber checks which indication applies to your situation.
• Zepbound vs Mounjaro: same drug, different label. This is the most common point of confusion, so it is worth being blunt: Zepbound and Mounjaro contain exactly the same active drug, tirzepatide, at the same doses, from the same manufacturer. The only difference is the approved use printed on the label. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and for obstructive sleep apnea. Which one you receive usually comes down to your diagnosis and what your insurance will cover, not to any difference in the medicine itself. Our Mounjaro vs Zepbound comparison walks through the practical implications, especially around insurance.
• How it works: GIP plus GLP-1. Zepbound activates two incretin receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1, both hormones your gut releases after eating. Through them it reduces appetite by acting on the brain, slows how fast your stomach empties so you stay full longer, supports glucose-dependent insulin release, and suppresses glucagon. The appetite effect is the headline for a weight drug, most people describe feeling satisfied with less food and thinking about it less. The working theory from the trials is that engaging both receptors produces a larger combined effect than GLP-1 alone, which is the most-cited reason tirzepatide came out ahead of semaglutide in the head-to-head data, though the precise role of GIP is still being studied.
• Dosing, as the label describes it. Zepbound uses a fixed escalation schedule, starting at a low dose and stepping up over several months to a maintenance target, designed to limit gut side effects. The starting dose is meant to build tolerance rather than to treat, and each increase is where symptoms tend to flare briefly before settling. Because Zepbound and Mounjaro are the same drug, the dose ladder is the same medicine, just labeled for a different use. The exact schedule and timing of increases are your prescriber's call against how you tolerate it; this describes the shape of the ramp, not a personal prescription. The shared principle across the whole class is that slow titration is what keeps the drug livable.

Frequently asked questions